WORLD PEPTIDEFOUNDATION

Bloodwork and peptide medications

Start with the exact product and the reason it is being considered. Bring its name, formulation, intended use, and your medication and supplement list. Check whether the evidence applies to that product and to people with a similar health concern. Then ask which results would help your clinician make a decision.

Panel map

Where a source connects a product to a test. An empty cell means this page cites no connection, not that none exists.
ProductGlucoseA1CIGF-1
WegovyPrescribing informationMonitoring instruction——
Egrifta WRPrescribing informationMonitoring instruction—Prescribing informationMonitoring instruction
BPC-157 (no approved product)———

How each connection is labelled

Prescribing information
Text in the approved product label for a named product, population and use.
Guideline
A recommendation from a professional guideline for a defined group and decision.
Human study
A marker a published human study measured as an outcome or safety measure.
Animal or laboratory research
A marker measured in animals or in the laboratory. It does not describe human care.
Evidence gap
A question the available sources do not answer.

The connections

Prescribing informationVerified 2026-11-06

Wegovy · semaglutide

In patients with diabetes mellitus, monitor blood glucose prior to starting WEGOVY and during WEGOVY treatment.
Section 2.1 (Important Monitoring and Administration Instructions); the same instruction appears in Section 5.4 (Hypoglycemia).
Role of the marker
Monitoring instruction
Formulation
Injection and tablets (one combined label)
Jurisdiction
United States (FDA-approved labeling on DailyMed)
Population in the source
Patients with diabetes mellitus (for the glucose-monitoring instruction)
Indication and status
Reduce major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; reduce excess body weight and maintain weight loss; the injection also has an indication for noncirrhotic MASH with moderate to advanced liver fibrosis in adults. See the label for the full indications and age groups.
What this does not establish
The instruction applies to patients with diabetes. It does not set a testing schedule or a target, and it does not describe a test everyone must have before treatment.

Question to bring: “Do I need a glucose monitoring plan, and what should I do if a reading concerns me?”

Source: DailyMed →Open the Glucose explainer →Watch the related WPF film →Search the directory →
Prescribing informationVerified 2026-11-06

Egrifta WR · tesamorelin

Evaluate glucose status prior to initiating EGRIFTA WR. Monitor all patients treated with EGRIFTA WR periodically to diagnose those who develop impaired glucose tolerance.
Section 5.4 (Glucose Intolerance or Diabetes Mellitus)
Role of the marker
Monitoring instruction
Formulation
For injection, 11.6 mg/vial kit
Jurisdiction
United States (FDA-approved labeling on DailyMed)
Population in the source
HIV-infected adult patients with lipodystrophy
Indication and status
Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label states it is not indicated for weight loss management and that long-term cardiovascular safety has not been established.
What this does not establish
The label does not give a testing interval in this section. The monitoring instruction does not make a person eligible for the product.

Question to bring: “Which tests are for safety, and how will we assess whether treatment is helping?”

Source: DailyMed →Open the Glucose explainer →Watch the related WPF film →Search the directory →
Prescribing informationVerified 2026-11-06

Egrifta WR · tesamorelin

EGRIFTA WR stimulates GH production and increases serum IGF-1. The effects of prolonged elevations in IGF-1 levels are unknown. Monitor IGF-1 levels during EGRIFTA WR therapy.
Section 5.2 (Elevated IGF-1 Levels)
Role of the marker
Monitoring instruction
Formulation
For injection, 11.6 mg/vial kit
Jurisdiction
United States (FDA-approved labeling on DailyMed)
Population in the source
HIV-infected adult patients with lipodystrophy
Indication and status
Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label states it is not indicated for weight loss management and that long-term cardiovascular safety has not been established.
What this does not establish
The label addresses IGF-1 as a safety consideration because treatment raises it. It does not say that IGF-1 shows whether the treatment is working, and this page does not repeat the label's discontinuation language as a threshold for anyone.

Question to bring: “Why are we following IGF-1 in my case, and what change would prompt discussion about the treatment plan?”

Source: DailyMed →Open the IGF-1 explainer →Watch the related WPF film →Search the directory →
Evidence gapVerified 2026-11-06

BPC-157 (no approved product)

FDA has identified no, or only limited, safety-related information for the proposed routes of administration, and describes risk for immunogenicity for certain routes and complexities with peptide-related impurities and API characterization.
FDA page entry for BPC-157, content current as of April 22, 2026
Role of the marker
No source-supported monitoring marker
Formulation
Compounded preparations proposed by nominators; no approved product label
Jurisdiction
United States (FDA human drug compounding list)
Population in the source
Not established. The FDA page reports no, or only limited, safety information for the proposed routes.
Indication and status
No approved indication. The FDA page lists BPC-157 among bulk drug substances nominated but withdrawn.
What this does not establish
The FDA page does not name a monitoring test for BPC-157. A Foundation editorial point, not an FDA statement: with these evidence gaps, a routine lab result cannot show that a given product, route or use is safe.

Question to bring: “What human evidence exists for the exact use and route being discussed?”

Source: U.S. Food and Drug Administration →Watch the related WPF film →Search the directory →

What this page does not do

  • It does not suggest a medication from any lab value.
  • It does not list a standard set of tests to have before treatment, a testing schedule, or a dose.
  • A monitoring instruction in a label applies to that product and population. It does not say a person qualifies for the product.

Sources and review status

  • Label text can change. Each card shows the date its source was checked, and the label itself is the current authority.

General education only. Bring your report, symptoms, and medication list to a qualified healthcare professional for advice about your care. Follow instructions from your lab or clinician if a result is marked critical.